NCT06936111View on ClinicalTrials.gov

REsiduAL rISk Under Intensive Lipid-lowering Therapy In Coronary Heart Disease

Not yet recruitingOBSERVATIONAL
Enrollment

900

Participants

Timeline

Start Date

July 31, 2025

Primary Completion Date

January 31, 2027

Study Completion Date

July 31, 2027

Conditions
Coronary Heart Disease (CHD)
Interventions
DIAGNOSTIC_TEST

Assessment of residual cholesterol and inflammatory risk factors

The prespecifed risk factors include CRP, SAA, TNF-α, IL-6, MCP-1, Lp-PLA2, PCSK-9, Lp(a)

Trial Locations (1)

Unknown

Shanghai Zhongshan Hospital, Shanghai

All Listed Sponsors
lead

Shanghai Zhongshan Hospital

OTHER

NCT06936111 - REsiduAL rISk Under Intensive Lipid-lowering Therapy In Coronary Heart Disease | Biotech Hunter | Biotech Hunter